ABSTRACT
Key Concepts ......................................................................................................... 271 Introduction ............................................................................................................ 272 Principles of Pharmacoeconogenomics ................................................................. 273
Cost-Effectiveness Analysis .............................................................................. 273 Cost-Utility Analysis ......................................................................................... 274 Cost-Benet Analysis ........................................................................................ 275 Cost-Minimization Analysis.............................................................................. 275
Practice of Pharmacoeconogenomics in Clinical Settings ..................................... 275 TPMT and the Thiopurine Drugs ...................................................................... 277 HER2 and Trastuzumab .................................................................................... 278 HLA B*5701 and Abacavir Hypersensitivity .................................................... 278 CYP2C9 and the Anticoagulant Warfarin .......................................................... 279 CYP2C19 and the Antiplatelet Drug Clopidogrel ............................................. 279
Economic Evaluation of Genetic Testing ...............................................................280 Conclusions and Future Perspectives ..................................................................... 281 Acknowledgments .................................................................................................. 282 Study Questions ..................................................................................................... 282 References ..............................................................................................................284
